Indegene Limited · NSE:INDGN
Indegene — Q4 FY2026 Earnings Presentation
27 slides from Indegene's earnings presentation, 2026
Slide 1: Investor Presentation Q4'26
Investor Presentation TM Q4’26
Slide 2: Disclaimer
Disclaimer This presentation may include opinions and assumptions about future performance which could be considered as forward-looking statements. Forward-looking statements intrinsically cover several risks and uncertainties, which may lead to a material difference between actual results and the s
Slide 3: FY26 and Q4 FY26 Annual and Quarterly Performance
FY 26 Q4 FY 26 Annual Performance Quarterly Performance A year of significant growth at scale Strong momentum continues into Q4 R E V E N U E F R O M O P E R A T I O N S ▲ 23.6% R E V E N U E F R O M O P E R A T I O N S ▲ 32.8% INR 35,105 M YoY in INR INR 10,034 M YoY in INR USD 396.9 M ▲ 18.2% USD
Slide 4: FY26 Business Highlights
FY26 Business Highlights Expanding customer base | Improving revenue productivity | Strengthening global delivery Customer Growth & Productivity Global Delivery Excellence ACTIVE CLIENT RELATIONSHIPS HEALTHCARE DELIVERY EXPERTISE Clients served during the year 91 Share of delivery team with domain s
Slide 5: Revenue Re-Acceleration with Resilient Margins & Cashflow
Revenue Re-Acceleration with Resilient Margins & Cashflow Strongest YoY growth in 3 years paired with stable 19%–20% EBITDA1 margins and 162% OCF to PAT ratio +23.6% 19.4% 162% FY26 Revenue Growth YoY FY26 EBITDA1 Margin FY26 OCF / PAT Ratio Strongest growth in years Steady across years High earning
Slide 6: Customer Strength — Recovery, Retention & Expansion
Customer Strength — Recovery, Retention & Expansion Top 5 Clients back to growth; 100%+ NRR with nil enterprise churn, and $1mn+ customer base up 29% YoY TOP 5 CUSTOMER RECOVERY RETENTION STRENGTH BROADENING CUSTOMER BASE $25mn+ customers: 2 → 3 ▲ 53 customers ▲ FY25 → FY26 NRR 100%+ $1mn+ revenue c
Slide 7: Management Commentary on Q4 FY26 results
Management Commentary on Q4 FY26 results Manish Gupta Suhas Prabhu Chairman and Chief Executive Officer Chief Financial Officer FY26 was a landmark year for Indegene. We surpassed ₹1,000 crore in FY26 reflected disciplined financial execution. Our cash conversion ratio of quarterly revenue for the f
Slide 8: Indegene is a natural beneficiary of GenAI
Indegene is a natural beneficiary of GenAI Five reinforcing dimensions- We are unique! And drive business value in a highly specialized and regulated Industry 01 02 03 04 05 Revenue Partner, Different Domain-led, Outcome-aligned Disruptor, not Cost Partner Buyer Group Judgment-intensive Commercial M
Slide 9: Indegene opportunity set expands with evolving AI
THE GENAI DIVIDEND Indegene opportunity set expands with evolving AI Commercial, medical affairs, regulatory — our North Stars are already in production, consolidating spend to a single AI-native specialist Commercial Medical Affairs Regulatory Engagement, content, omnichannel Writing, MLR, pharmaco
Slide 10: Indegene's Structural Differentiation & Impact
Indegene’s Structural Differentiation & Impact Built over 27 years into our DNA & business model — and already visible in customer outcomes WHY GENAI FITS INDEGENE PROOF - OUTCOMES IN MOTION Three structural advantages we have been compounding for years Productivity unlocks plus flagship customer ma
Slide 11: Awards, Recognitions & Certifications
Awards, Recognitions & Certifications A people-first culture backed by independent ESG and workplace recognitions - management, diversity, well-being, governance and cyber resilience NSE ESG Rating 80 / 100 LEADER E 86 S 76 G 77 Company with Great Managers 2025 Great Manager Awards 2025 Great Place
Slide 12: Financial Highlights
Financial High imdegene’
Slide 13: FY26: Consolidated & Ex-BioPharm Financials
FY26: Consolidated & Ex-BioPharm Financials Consolidated Ex-BioPharm* Consolidated Ex-BioPharm* Particulars FY26 FY26 FY25 YoY % YoY % Revenue from Operations 35,105 33,163 28,393 23.6% 16.8% Employee Benefit Expenses 21,977 21,081 18,152 21.1% 16.1% Other Expenses 6,790 6,242 4,898 38.6% 27.4% Othe
Slide 14: Q4 FY26: Consolidated & Ex-BioPharm Financials
Q4 FY26: Consolidated & Ex-BioPharm Financials Consolidated Ex-BioPharm* Consolidated Ex-BioPharm* Consolidated Ex-BioPharm* Particulars Q4 FY26 Q4 FY26 Q3 FY26 Q3 FY26 Q4 FY25 QoQ % YoY % QoQ % YoY % Revenue from Operations 10,034 8,994 9,421 8,520 7,556 6.5% 32.8% 5.6% 19.0% Employee Benefit Expen
Slide 15: Profitability Metrics — Adjusted vs Ind AS / Reported
Profitability Metrics — Adjusted vs Ind AS / Reported Amount in INR Mn EBITDA PBT PAT Q4 FY26 FY26 Q4 FY26 FY26 Q4 FY26 FY26 Revenue 10,034 35,105 10,034 35,104 10,034 35,105 Adjusted EBITDA/PBT/PAT 1,889 6,793 1,495 6,000 1,133 4,583 Adjusted EBITDA/PBT/PAT % 18.8% 19.4% 14.9% 17.1% 11.3% 13.1% Adj
Slide 16: Segment Performance
Segment Performance Amount in INR Mn Segment performance QoQ Segment performance YoY 7,193 6,689 24,605 1,040 1,942 902 5,787 6,153 19,348 22,663 2,387 2,537 8,025 9,297 346 304 1,020 1,202 ECS EMS OTHERS ECS EMS OTHERS BioPharm Q3 FY26 Q4 FY26 BioPharm FY25 FY26 • Core segments (ECS & EMS) grew 7.2
Slide 17: FY26: Stable Business mix
FY26: Stable Business mix Revenue from Service offering ($Mn) Revenue by Customer Industry (%) * Revenue by Customer Geography (%) 3.6% 1.7% 335.7 396.9 3.4% 3.6% 3.4% 2.4% 25.5% 71.6% 68.1% 70.1% 0.5% 91.3% 28.3% 26.5% FY25 FY26 FY26 FY26 Enterprise Medical Solutions Enterprise Commercial Solutions
Slide 18: Two Growth Engines Driving Revenue Expansion
Two Growth Engines Driving Revenue Expansion Deeper penetration of top accounts and a wider, taller client pyramid are compounding revenue growth GROWT H A PPROA C H 1 GROWT H A PPROA C H 2 Deeper Engagement with Large Pharma Broader Targeting — Wider, Taller Pyramid 14.1% YoY 7.0% YoY 3 of 5 91 53
Slide 19: Annexure
Annexure imdegene’
Slide 20: We operate at the intersection of healthcare and technology
We operate at the intersection of healthcare and technology Tech-Led Healthcare Delivery and Expertise Digital Capabilities Healthcare market understanding In-depth domain knowledge Digital-first approach GenAI based tools and platform Navigating regulatory landscape Medical content know-how Drive t
Slide 21: Our large addressable market is underpinned by growing outsourcing and rapid digital adoption
Our large addressable market is underpinned by growing outsourcing and rapid digital adoption Large Market Opportunity Outsourcing and Tech Lifesciences at Inflection We Offer Solutions Expanding our TAM Point Across Life Sciences Life Sciences Operations Spend Across End Markets Verticals ($B) Pate
Slide 22: Full-Stack Capabilities & GenAI Platforms Driving Multi-Quarter Operating Model Transformation
Full-Stack Capabilities & GenAI Platforms Driving Multi-Quarter Operating Model Transformation Full-Stack, Diverse Capabilities with • Consulting services & management of entire commercial Complex Skillsets Top 10 and marketing operations in US for a multi-product portfolio Omnichannel Pharma Strate
Slide 23: Dual-Pronged Gen AI Strategy: Accelerate value for clients today while building for tomorrow
Dual-Pronged Gen AI Strategy: Accelerate value for clients today while building for tomorrow Existing Products New Products New Areas/Capabilities Extend capabilities of existing products to capture more value Unlock value from new avenues that have opened up due to EXTEND via cross-sell/up-sell (Ne
Slide 24: AI-Led Innovation across Commercial Value Chain
AI-Led Innovation across Commercial Value Chain Strategy & Brand Planning Content Evolution Content Studio Content Operations & Deployment Brand Planning Evolution Localization Omnichannel Defining the strategic Evolve brand concept Localize Creative Content Orchestration direction of the brand and
Slide 25: Thank You!
Thank You! www.indegene.com
Slide 26: Fact Sheet
Fact Sheet Consolidated Financial Data - Fourth Quarter, Fiscal 2026 Operational & Financial Metrics Key performance indicators (in INR Mn) Quarter ended Growth Year ended SI. Particulars Mar 31, Dec 31, Mar 31, March 31, March 31, No. YoY QoQ 2026 2025 2025 2026 2025 1. Active clients(1)(No.) 91 84
Slide 27: Fact Sheet
Fact Sheet Consolidated Financial Data - Fourth Quarter, Fiscal 2026 Revenue by customer industry (in %) Quarter ended (contribution) Growth Particulars Mar 31, Dec 31, Mar 31, YoY QoQ 2026 2025 2025 Biopharma 89.9 89.9 94.0 27.0 6.6 Medical Devices 3.9 4.2 2.6 97.9 -1.9 Emerging Biotech 4.6 3.4 2.3